Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H11N3OS |
| Molecular Weight | 245.3 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1=C2CS[C@@H](N2C=C1)C3=CC=CN=C3
InChI
InChIKey=ARFOASMERCHFBY-GFCCVEGCSA-N
InChI=1S/C12H11N3OS/c13-11(16)9-3-5-15-10(9)7-17-12(15)8-2-1-4-14-6-8/h1-6,12H,7H2,(H2,13,16)/t12-/m1/s1
| Molecular Formula | C12H11N3OS |
| Molecular Weight | 245.3 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Dacopafant (R-enantiomer RP 55778, racemate RP 48740) is an antagonist fo a platelet-activating factor and an inhibitor of TNH-alpha synthesis. It was developed by Rhone-Poulenc Rorer (France, now Aventis). In vitro, treatment of HIV-1 infected monocyte-derived macrophages with dacopafant resulted in a significant decrease in TNF-alpha levels and viral production. RP 48740 inhibited [3H]PAF platelet binding with IC50 of 2.3 uM and antagonized PAF-induced platelet activation with IC50 of 16 uM. In a clinical trial on human volunteers, RP 48740 was well tolerated and inhibited ex vivo platelet aggregation by as much as 79% 6 hr after administration.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides. | 1997-04 |
|
| Infection of human macrophages with an endogenous tumour necrosis factor-alpha (TNF-alpha)-independent human immunodeficiency virus type 1 isolate is unresponsive to the TNF-alpha synthesis inhibitor RP 55778. | 1994-06 |
|
| A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells. | 1993-03-15 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:41:25 GMT 2025
by
admin
on
Wed Apr 02 08:41:25 GMT 2025
|
| Record UNII |
H1T03Z1G60
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
205955
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
DTXSID201176088
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
6584
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
C73132
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
125372-33-0
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
H1T03Z1G60
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL67588
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
SUB06886MIG
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY | |||
|
100000083992
Created by
admin on Wed Apr 02 08:41:25 GMT 2025 , Edited by admin on Wed Apr 02 08:41:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|